IL315556A - Methods for treating active eosinophilic esophagitis - Google Patents

Methods for treating active eosinophilic esophagitis

Info

Publication number
IL315556A
IL315556A IL315556A IL31555624A IL315556A IL 315556 A IL315556 A IL 315556A IL 315556 A IL315556 A IL 315556A IL 31555624 A IL31555624 A IL 31555624A IL 315556 A IL315556 A IL 315556A
Authority
IL
Israel
Prior art keywords
eoe
week
patient
baseline
esophageal
Prior art date
Application number
IL315556A
Other languages
English (en)
Hebrew (he)
Inventor
Allen Radin
Jennifer D Hamilton
Leda Mannent
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Allen Radin
Jennifer D Hamilton
Leda Mannent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology, Allen Radin, Jennifer D Hamilton, Leda Mannent filed Critical Regeneron Pharma
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of IL315556A publication Critical patent/IL315556A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL315556A 2017-08-04 2018-08-02 Methods for treating active eosinophilic esophagitis IL315556A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US201762561593P 2017-09-21 2017-09-21
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Publications (1)

Publication Number Publication Date
IL315556A true IL315556A (en) 2024-11-01

Family

ID=63113646

Family Applications (2)

Application Number Title Priority Date Filing Date
IL315556A IL315556A (en) 2017-08-04 2018-08-02 Methods for treating active eosinophilic esophagitis
IL272245A IL272245B2 (en) 2017-08-04 2018-08-03 Methods for treating active eosinophilic esophagitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL272245A IL272245B2 (en) 2017-08-04 2018-08-03 Methods for treating active eosinophilic esophagitis

Country Status (9)

Country Link
EP (1) EP3661551A1 (enExample)
JP (2) JP7417515B2 (enExample)
KR (2) KR102719720B1 (enExample)
CN (1) CN111032084A (enExample)
AU (2) AU2018311981B2 (enExample)
CA (1) CA3071528A1 (enExample)
IL (2) IL315556A (enExample)
MA (1) MA49744A (enExample)
MX (2) MX2020001305A (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7862322B2 (ja) * 2020-05-22 2026-05-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
GB202102277D0 (en) * 2021-02-18 2021-04-07 Nordic Bioscience As Immunoassay for detecting Eosinophilic Esophagitis
EP4091615A1 (en) * 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CN117085122A (zh) * 2022-04-29 2023-11-21 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白

Also Published As

Publication number Publication date
RU2020109331A (ru) 2021-09-06
JP2024016237A (ja) 2024-02-06
AU2025200955A1 (en) 2025-03-06
EP3661551A1 (en) 2020-06-10
IL272245A (en) 2020-03-31
AU2018311981B2 (en) 2024-11-14
AU2018311981A1 (en) 2020-02-20
MX2024012777A (es) 2024-11-08
KR102719720B1 (ko) 2024-10-22
CA3071528A1 (en) 2019-02-07
JP7417515B2 (ja) 2024-01-18
JP2020529434A (ja) 2020-10-08
IL272245B2 (en) 2025-02-01
IL272245B1 (en) 2024-10-01
KR20240152980A (ko) 2024-10-22
KR20200035442A (ko) 2020-04-03
JP7811933B2 (ja) 2026-02-06
CN111032084A (zh) 2020-04-17
MX2020001305A (es) 2020-03-09
MA49744A (fr) 2020-06-10
RU2020109331A3 (enExample) 2021-12-28

Similar Documents

Publication Publication Date Title
US11053309B2 (en) Methods for treating active eosinophilic esophagitis
US12291571B2 (en) Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
US20250154267A2 (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
JP7811933B2 (ja) 活動性好酸球性食道炎を治療する方法
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
HK40029391A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
EA045955B1 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
HK1218854B (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor